1.
Non-Small Cell Lung Cancer Market
Analysis, Market Share, Market Research
Report, Leading Companies
LAS VEGAS, April 28, 2020 -- The growth of NSCLC Market is expected to
increase due to increasing incident cases of NSCLC, continuous uptake of
approved therapies mainly immune checkpoint inhibitors, increasing use of
biomarker testing, probable entry of potential premium price emerging
therapies and increasing awareness of mutations, among others.
DelveInsight has introduced a new Market Insights, Epidemiology, and Market
Forecast Report on "Non-Small Cell Lung Cancer Market Insights,
Epidemiology, and Market Forecast-2030" to its portfolio.
Key Highlights from report are:
 As per the DelveInsight analysis, the total incident cases of NSCLC in the
7MM were observed to be 484,726 cases in the year 2017. These cases
are expected to grow with a significant CAGR in the study period 2017–
2030.
 There are different types of treatment available for NSCLC; however,
mainly 10 types of standard treatment are used, which include Surgery,
Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy,
Laser therapy, Photodynamic therapy (PDT), Cryosurgery,
Electrocautery, and Watchful waiting.
 The market size of NSCLC in the 7MM is expected to increase during
study period. According to the estimates, the highest contribution in the
market size of NSCLC is from the United States followed
by Japan, Germany, and the UK.

2.
 One of the most exciting developments in lung cancer medicine is the
introduction of targeted treatments.
Request for free sample pages to know more on Non-Small Cell Lung Cancer
Market Forecast
NSCLC is the most common type of lung cancer accounted for approximately
85% of all lung cancers. The disease epidemiology included in the report
provides historical as well as forecasted Non-Small Cell Lung Cancer
epidemiology, which is segmented as Total Incident cases of NSCLC patients,
Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of
NSCLC patients by Stages, Total NSCLC cases of patients by Genetic
mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of
Therapies scenario of NSCLC in the 7MM.
The total NSCLC incident cases in the 7MM were observed to be 484,726 cases
in 2017.

3.
Click here to know more on Non-Small Cell Lung Cancer pipeline
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer
marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek
(Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq
(Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in
combination with Mekinist (Trametinib), Tagrisso (osimertinib),
Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib),
Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along
with many more.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential
products such as
 Nazartinib (EGF816)
 Capmatinib (INC280)
 Tepmetko (tepotinib)
 Merestinib
 JNJ-61186372 (JNJ-6372)
 Vemurafenib Plus Cobimetinib
 X-396 (Ensartinib)
 Tedopi (OSE2101)
 Selpercatinib (LY3527723/ LOXO-292)
 SAR408701
 Braftovi (encorafinib) + Mektovi (binimetinib)
 PADCEV (enfortumab vedotin/ASG-22ME)
 Pralsetinib (BLU-667)
 TAK-788: Canakinumab (ACZ885)
 Avelumab (Bavencio)
 Veliparib (ABT-888): Sitravatinib (MGCD516)
 Tesevatinib
 Romiplostim: Cabozantinib
 Sym015
 AMG 510
 INCMGA00012 (MGA012)

4.
 Libtayo (Cemiplimab)
 Bavituximab
 M7824 (Bintrafusp alfa)
 And many others
Key Players covered in the report are:-
 Novartis Pharmaceuticals
 Merck KGaA
 Eli Lilly and Company
 Janssen Research & Development
 Hoffmann-La Roche
 Xcovery
 BeyondSpring Pharmaceuticals
 OSE Immunotherapeutics
 Sanofi
 Pfizer
 Astellas Pharma
 Seattle Genetics
 Blueprint Medicines Corporation
 Takeda
 AbbVie
 Kadmon Corporation
 Amgen
 Symphogen
 Regeneron Pharmaceuticals
 Peregrine Pharmaceuticals
 Avid Bioservices
 GlaxoSmithKline
And many others
The report includes provides in depth analysis historical and forecasted Market
Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by
Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of
BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total
Market Size of ALK as well.
Market Driver

5.
Market Barrier
The reasons for buying this report:
 The report proffers an overview of pathophysiology, various diagnostic
approaches and NSCLC treatment algorithm, including detailed chapters
for marketed products and emerging therapies.
 Historical and forecasted Non-Small Cell Lung Cancer epidemiology in
7MM covering the United States, EU5 (Germany, France, Italy, Spain,
and the United Kingdom), and Japan from 2017-2030.
 Detailed historical and forecasted NSCLC market covering the United
States, EU5 and Japan from 2017-2030.
 Pipeline analysis across different stages of development (Phase III and
Phase II), different emerging trends and comparative analysis of pipeline
products with comprehensive clinical profiles, key cross-competition,
launch date along with product development activities.
 Detailed Non-Small Cell Lung Cancer market size by therapies,
covering the United States, EU5 and Japan from 2017-2030.

6.
 Reimbursement scenario and Key Opinion Leader Views
Table of Contents
1. Key Insights
2. Executive Summary of NSCLC
3. SWOT Analysis of NSCLC
4. NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country
4.3. Total Market Share (%) Distribution of NSCLC in 2017: By Mutations/
biomarkers
4.4. Total Market Share (%) Distribution of NSCLC in 2030: By Mutations/
biomarkers
4.5. NSCLC Revenue Summary by Mutations/ biomarkers
5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC

7.
6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the
United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in
Germany
8.2. France

8.
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United
Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United
Kingdom
8.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the
United Kingdom
9. Japan Epidemiology
9.1. Japan

9.
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan
10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines:
2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice
Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines:
2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. Marketed Therapies
14.1. Key Cross

10.
14.2. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.3. Imfinzi (Durvalumab): AstraZeneca
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity
14.3.6. Safety and Efficacy of Ongoing Clinical Trials
14.4. Opdivo (Nivolumab): Bristol-Myers Squibb
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Other Developmental Activities
14.4.4. Pivotal Clinical Trials
14.4.5. Ongoing Current Pipeline Activity
14.5. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.5.1. Product Description
14.5.2. Regulatory Milestones

11.
14.5.3. Other Developmental Activities
14.5.4. Pivotal Clinical Trials
14.5.5. Ongoing Current Pipeline Activity
14.6. Keytruda (Pembrolizumab): Merck
14.6.1. Product Description
14.6.2. Regulatory Milestones
14.6.3. Other Developmental Activities
14.6.4. Pivotal Clinical Trials
14.6.5. Ongoing Current Pipeline Activity
14.7. Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis
14.7.1. Product Description
14.7.2. Regulatory Milestones
14.7.3. Other Developmental Activities
14.7.4. Pivotal Clinical Trials
14.8. Tagrisso(Osimertinib): AstraZeneca
14.8.1. Product Description
14.8.2. Regulatory Milestones
14.8.3. Other Developmental Activities
14.8.4. Pivotal Clinical Trials
14.8.5. Ongoing Current Pipeline Activity
14.9. Lorbrena/Lorviqua (Lorlatinib): Pfizer
14.9.1. Product Description

12.
14.9.2. Regulatory Milestones
14.9.3. Other Developmental Activities
14.9.4. Pivotal Clinical Trials
14.9.5. Ongoing Current Pipeline Activity
14.10. Vizimpro(Dacomitinib): Pfizer
14.10.1. Product Description
14.10.2. Regulatory Milestones
14.10.3. Other Developmental Activities
14.10.4. Pivotal Clinical Trials
14.10.5. Ongoing Current Pipeline Activity
14.11. Alunbrig (Brigatinib): Takeda Pharmaceuticals
14.11.1. Product Description
14.11.2. Regulatory Milestones
14.11.3. Pivotal Clinical Trials
14.11.4. Ongoing Current Pipeline Activity
14.11.5. Safety and Efficacy of Ongoing Clinical Trials
14.12. Alecensa (Alectinib): Hoffmann-La Roche
14.12.1. Product Description
14.12.2. Regulatory Milestones
14.12.3. Other Developmental Activities
14.12.4. Pivotal Clinical Trials
14.12.5. Ongoing Current Pipeline Activity

13.
14.13. Vitrakvi (Larotrectinib): Bayer Healthcare
14.13.1. Product Description
14.13.2. Regulatory Milestones
14.13.3. Other Developmental Activities
14.13.4. Pivotal Clinical Trials
14.13.5. Safety and Efficacy
14.14. Portrazza (Necitumumab): Eli Lilly
14.14.1. Product Description
14.14.2. Regulatory Milestones
14.14.3. Other Developmental Activities
14.14.4. Pivotal Clinical Trials
14.14.5. Ongoing Current Pipeline Activity
15. Emerging Therapies
15.1. Nazartinib (EGF816): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy
15.2. Capmatinib (INC280): Novartis Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy

14.
15.3. Tepmetko (tepotinib): Merck KGaA
15.3.1. Product Description
15.3.2. Other Development Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Merestinib: Eli Lilly and Company
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Telisotuzumab Vedotin: AbbVie
15.4.4. Product Description
15.4.5. Clinical Development
15.4.6. Safety and Efficacy
15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.5.1. Product Description
15.5.2. Other Development Activity
15.5.3. Clinical Development
15.5.4. Safety and Efficacy
15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.6.1. Product Description
15.6.2. Clinical Development
15.6.3. Safety and Efficacy
15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche

15.
15.7.1. Product Description
15.7.2. Clinical Development
15.7.3. Safety and Efficacy
15.8. X-396 (Ensartinib): Xcovery
15.8.1. Product Description
15.8.2. Clinical Development
15.8.3. Safety and Efficacy
15.9. Plinabulin: BeyondSpring Pharmaceuticals
15.9.1. Product Description
15.9.2. Clinical Development
15.9.3. Safety and Efficacy
15.10. Tedopi (OSE2101): OSE Immunotherapeutics
15.10.1. Product Description
15.10.2. Clinical Development
15.10.3. Safety and Efficacy
15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company
15.11.1. Product Description
15.11.2. Clinical Development
15.11.3. Safety and Efficacy
15.12. SAR408701: Sanofi
15.12.1. Product Description
15.12.2. Clinical Development

16.
15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
15.13.1. Product Description
15.13.2. Clinical Development
15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle
Genetics
15.14.1. Product Description
15.14.2. Clinical Development
15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation
15.15.1. Product Description
15.15.2. Clinical Development
15.15.3. Safety and Efficacy
15.16. TAK-788: Takeda
15.16.1. Product Description
15.16.2. Clinical Development
15.16.3. Safety and Efficacy
15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals
15.17.1. Product Description
15.17.2. Clinical Development
15.18. Avelumab (Bavencio): Merck KGaA and Pfizer
15.18.1. Product Description
15.18.2. Clinical Development
15.18.3. Safety and Efficacy
15.19. Veliparib (ABT-888): AbbVie

17.
15.19.1. Product Description
15.19.2. Clinical Development
15.19.3. Safety and Efficacy
15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers
Squibb/Beigene
15.20.1. Product Description
15.20.2. Other Developmental Activities
15.20.3. Clinical Development
15.20.4. Safety and Efficacy
15.21. Tesevatinib: Kadmon Corporation
15.21.1. Product Description
15.21.2. Clinical Development
15.21.3. Safety and Efficacy
15.22. Romiplostim: Amgen
15.22.1. Product Description
15.22.2. Clinical Development
15.23. Cabozantinib: Exelixis/Ipsen/Takeda
15.23.1. Product Description
15.23.2. Other Development Activities
15.23.3. Clinical Development
15.23.4. Safety and Efficacy
15.24. Sym015: Symphogen
15.24.1. Product Description

18.
15.24.2. Clinical Development
15.24.3. Safety and Efficacy
15.25. AMG 510: Amgen
15.25.1. Product Description
15.25.2. Clinical Development
15.25.3. Safety and Efficacy
15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited
15.26.1. Product Description
15.26.2. Clinical Development
15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.27.1. Product Description
15.27.2. Clinical Development
15.27.3. Safety and Efficacy
15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc
15.28.1. Product Description
15.28.2. Clinical Development
15.28.3. Safety and Efficacy
15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
15.29.1. Product Description
15.29.2. Clinical Development
15.29.3. Safety and Efficacy
16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis

19.
16.1. Key Findings
16.2. Market Outlook: 7MM
17. PD-L1—Market Size
17.1. Total Market Size of PD-L1 NSCLC in the 7MM
17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of PD-L1 NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of PD-L1 NSCLC in Japan
18. BRAF Mutation—Market Size
18.1. Total Market Size of BRAF NSCLC in the 7MM
18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM
18.3. United States Market Size
18.3.1. Total Market size of BRAF NSCLC in the United States
18.4. EU-5 Market Size
18.4.1. Germany Market Size

20.
18.4.2. France Market Size
18.4.3. Italy Market Size
18.4.4. Spain Market Size
18.4.5. United Kingdom Market Size
18.5. Japan Market Size
18.5.1. Total Market size of BRAF NSCLC in Japan
19. c-MET Mutation—Market Size
19.1. Total Market Size of c-MET NSCLC in the 7MM
19.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM
19.3. United States Market Size
19.3.1. Total Market size of c-MET NSCLC in the United States
19.4. EU-5 Market Size
19.4.1. Germany Market Size
19.4.2. France Market Size
19.4.3. Italy Market Size
19.4.4. Spain Market Size
19.4.5. United Kingdom Market Size
19.5. Japan Market Size
19.5.1. Total Market size of c-MET NSCLC in Japan
20. EGFR Mutation—Market Size
20.1. Total Market Size of EGFR-positive NSCLC in the 7MM
20.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM

21.
20.3. United States Market Size
20.3.1. Total Market size of EGFR NSCLC in the United States
20.4. EU-5 Market Size
20.4.1. Germany Market Size
20.4.2. France Market Size
20.4.3. Italy Market Size
20.4.4. Spain Market Size
20.4.5. United Kingdom Market Size
20.5. Japan Market Size
20.5.1. Total Market size of NSCLC in Japan
21. ALK-Mutation—Market Size
21.1. Total Market Size of ALK NSCLC in the 7MM
21.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM
21.3. United States Market Size
21.3.1. Total Market size of ALK NSCLC in the United States
21.4. EU-5 Market Size
21.4.1. Germany Market Size
21.4.2. France Market Size
21.4.3. Italy Market Size
21.4.4. Spain Market Size
21.4.5. United Kingdom Market Size
21.5. Japan Market Size

22.
21.5.1. Total Market size of NSCLC in Japan
22. Market Access and Reimbursement of NSCLC Therapies
23. Market Drivers of NSCLC
24. Market Barriers of NSCLC
25. Appendix
25.1. Bibliography
25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
Request a Webex Demo to get a walk-through of the
report: https://www.delveinsight.com/sample-request/non-small-cell-lung-
cancer-market
Related Reports:
 Non-Small Cell Lung Cancer Epidemiology Forecast to 2030
 Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2020
 Non-Small Cell Lung Cancer Pipeline Insights, 2020
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm,
focused exclusively on the life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and
Medical devices companies formulate prudent business decisions for
improving their performances to stay ahead of the competitors.